Bugyeong Son

Bugyeong Son

Auto-generated profile, based on publicly available information

Bugyeong Son

Department of Public Health Sciences, College of Medicine Hanyang University Seoul Republic of Korea

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2026 in Geriatrics & Gerontology International
Verified
Journal Article
Closed access
HYHyunok Yun
Hyunok Yun
BSBugyeong Son
Bugyeong Son
PSPildoo Sung
Pildoo Sung

1 January 2026 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
ABAbdurahman Bura
Abdurahman Bura
MNMin-Young Noh
Min-Young Noh
WSWonjae Sung
Wonjae Sung
BSBugyeong Son
Bugyeong Son
IRIsabel Rea
Isabel Rea
SKSeung hyun Kim
Seung hyun Kim
Bura A, et al. J Clin Neurol. 2026 Nov;22(6):693-708. https://doi.org/10.3988/jcn.2026.0289

1 January 2026 in Journal of Clinical Neurology
Verified
Journal Article
Open access
SJSarah M. Jacob
Sarah M. Jacob
BSBugyeong Son
Bugyeong Son
SBSahar Bagheri
Sahar Bagheri
SLSukyoung Lee
Sukyoung Lee
JLJamie Nicole Leckie
Jamie Nicole Leckie
Gerald PfefferGerald Pfeffer
Gerald Pfeffer
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of upper and lower motor neurons leading to progressive disability and death. Approximately 10% of cases are caused by single-gene disorders with the remaining 90% of cases presumed to be caused by a combination of environmental and genetic factors. The microbiome (the ensemble of microorganisms that colonize body surfaces and organs) was recently identified for its importance in the pathogenesis of ALS. In this study, we recruited 100 participants from two ethnically and geographically distinct sites (71 from Calgary, Canada, and 29 from Seoul, Republic of Korea) which included 59 ALS participants and 41 controls. All participants provided saliva samples for oral microbial analysis using 16S rRNA sequencing. Basic demographic information was collected from all participants, and ALS participants provided additional clinical information including site of disease onset, disease duration, and ALS Functional Rating Scale - Revised score. Significant differences in beta diversity of the oral microbiomes were seen between limb- and bulbar-onset ALS participants. Two bacterial genera were differentially abundant between these groups, Bifidobacteriaceae Bifidobacterium was enriched in bulbar-onset cases, while Pasteurellaceae Haemophilus was enriched in limb-onset cases. No significant differences were found between ALS participants and controls, but there were significant differences when comparing participants from different sites of recruitment. Amongst household pairs (n=35 pairs), ALS participants differed from control participants at the Seoul site. Despite the cohort and household effects, our study identified differentially abundant organisms that may be important to the phenotypic variability of ALS and should be considered for future study. Our study provides novel insights into design for future multi-site microbiome research in ALS.

1 July 2026 in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Verified
Journal Article
Open access
MNMin‐Young Noh
Min‐Young Noh
WSWonjae Sung
Wonjae Sung
HKHyunkee Kim
Hyunkee Kim
BSBugyeong Son
Bugyeong Son
YKYoung‐Eun Kim
Young‐Eun Kim
SKSeung hyun Kim
Seung hyun Kim
Introduction: The presenilin 1 (PSEN1) p .Met233Val variant is a Dominantly Inherited Alzheimer Network–Trials Unit (DIAN‐TU)–eligible autosomal‐dominant Alzheimer's disease (ADAD) variant for which lecanemab response data are unavailable. Methods: A 34‐year‐old symptomatic PSEN1 p .Met233Val carrier (APOE ε3/ε3) was prospectively followed through 26 lecanemab infusions over 12 months, with serial magnetic resonance imaging (MRI), amyloid positron emission tomography (PET), and plasma biomarkers. Results: No amyloid‐related imaging abnormalities occurred. Composite Centiloid increased modestly (+7.2), masking regional divergence: basal ganglia (−24.5) and medial temporal cortex (−22.1) declined, whereas posterior cortical regions accrued amyloid. Plasma amyloid beta (Aβ) 42/40 rose to 122% by T22, with concurrent decreases in phosphorylated tau at threonine 217 (p‐tau217), p‐tau181, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP). Global Clinical Dementia Rating (CDR) score remained 0.5; caregiver reports noted improvements in spasticity, dystonia, and affective features. Discussion: Lecanemab demonstrated neuroimaging safety and evidence of biological target engagement in this symptomatic PSEN1 p .Met233Val ADAD carrier. These longitudinal neuroimaging and plasma biomarker findings may help inform interpretation of treatment responses in genetically defined ADAD.